ESMO Advanced Course on
Unsolved questions in Immuno-Oncology
16-17th February 2018, Amsterdam, Netherlands

Co-Chairs: John B.A.G. Haanen, Netherlands
Martin Reck, Germany

Speakers: Stéphane Champiat, France
Keith Kerr, United Kingdom
Aurélien Marabelle, France
Erika Martinelli, Italy
Matthias Preusser, Austria

Learning Objectives
• The development of immuno-therapy in Medical Oncology has been practice changing for several frequent tumour types and established Immunotherapy as an additional class of therapeutics
• Patient selection based of immune biomarkers may be associated with efficacy (predictive factor) but still remains controversial and other biomarkers could help in patient selection
• The mechanism of action of Immune Check Point Inhibitors differs greatly from conventional cancer treatment and efficacy evaluation needs to be adapted
• The systemic manipulation of the Immune system has proven efficacy against cancer cells but may also be associated with alteration of normal tissues or organs, targeted by Immune Check Point Inhibitors and consequently auto-immune or auto-immune-like side effects have been reported

Accreditation
The programme of this event has been accredited with 10 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

Acknowledgements
This event is supported by an unrestricted educational grant.
**Friday 16th February**

**09:00-09:40  Welcome and Introduction**
Welcome
John B.A.G. Haanen, NL

The present state-of-the-art of Immune Check-point Inhibitors in oncology
John B.A.G. Haanen, NL

**09:40-10:40  Session 1 – Patient selection**
Is there a clear correlation between PD-L1 expression and outcome? The Medical Oncologist point of view
Martin Reck, DE

Strengths and weaknesses of PD-L1 testing: the pathologist point of view
Keith Kerr, UK

**10:40-11:10  Coffee Break**

**11:10-11:40  Session 1 – cont. Patient selection**
Immunogram, immunoprofiling, immunoscores and other biomarkers of potential use
John B.A.G. Haanen, NL

**11:40-12:10  Session 2 – Immune-related toxicities**
ESMO Guidelines: management of toxicities from immune checkpoint inhibitors
John B.A.G. Haanen, NL

**12:10-13:10  Lunch**

**13:10-15:10  Session 3 – Special situations**
Patients with brain metastasis
Matthias Preusser, AT

Patients with liver metastasis or liver primary tumours
Erika Martinelli, IT

Patients with previous organ transplant
Stéphane Champiat, FR

The issue of fast progression
Stéphane Champiat, FR

**15:10-15:40  Coffee break**

**15:40-16:40  Session 4 – Treatment delivery: dosing and duration**
Are patients overdosed with the present recommendations?
Aurélien Marabelle, FR

Should treatment be prolonged indefinitely? Could a maintenance phase be used?
John B.A.G. Haanen
Saturday 17th February

9:00-12:30  Workshops sessions
  Three parallel workshops sessions with 20 delegates in each group (delegates will attend all 3
  sessions on a rotation basis)
  15’ Introduction based on clinical cases presented by speakers
  35’ Discussion
  10’ Break

Workshop 1  Patient selection based on selected biomarkers
  Martin Reck, DE

Workshop 2  Immune-related toxicity and duration of treatment
  Aurélien Marabelle, FR
  John B.A.G Haanen, NL

11:00-11:30  Coffee Break

Workshop 3  Special situations
  Stéphane Champiat, FR
  Matthias Preusser, AT
  Erika Martinelli, IT

12:30-13:15  Feedback on the workshop from each group

13:15-13:30  Synthesis and wrap-up
  John B.A.G. Haanen

13:30-14:30  Lunch